📰 Pascal Touchon News
Page 2 - Pascal Touchon News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pascal Touchon. Real-time updates on events, politics, business and more.
November 22, 2023
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and...
November 10, 2023
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and...
November 10, 2023
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...
November 9, 2023
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) shares are trading lower after the company said that primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS) did not meet the primary endpoint of confirmed disability improvement (CDI) by expanded disabi
November 8, 2023
Primary Endpoint of Confirmed Disability Improvement at 12 Months Not Achieved Company to Further Analyze Data and Evaluate Strategic Options for ATA188 Program with Focusing of Resources and...
November 5, 2023
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2023 Earnings Call Transcript November 4, 2023 Operator: Good morning, and thank you for standing by. Welcome to Atara Biotherapeutics’ Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s call is being recorded. I would now like to hand the call over to Alex Chapman, […]
November 5, 2023
Operator: Good morning, and thank you for standing by. Welcome to Atara Biotherapeutics’ Third Quarter 2023 Financial Results Conference Call.
November 3, 2023
/PRNewswire/ -- Pierre Fabre Laboratories announced today an expanded global partnership with Atara Biotherapeutics, a leader in T-cell immunotherapy,...
November 1, 2023
Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel®, including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets Atara to...
October 31, 2023
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totalling 12,270,000 shares, an increase of 6.3% from the September 30th total of 11,540,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the days-to-cover […]